Evidence map›Paper›PMID 41030121›Full record

ArticleAnnals of clinical and translational neurology2026

Nationwide Characterization of MFN2-Related CMT in 176 Japanese Patients: Clinical and Genetic Insights.

Masahiro Ando, Yujiro Higuchi, Jun-Hui Yuan, Akiko Yoshimura, Chikashi Yano, Takahiro Hobara, Fumikazu Kojima, Yu Hiramatsu, Satoshi Nozuma, Tomonori Nakamura and 4 more

Abstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. BiallelicJournal of neuromuscular diseases · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masahiro AndoDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-6187-9042
Yujiro HiguchiDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-5579-4384
Jun-Hui YuanDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-3808-7813
Akiko YoshimuraDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-1768-3181
Chikashi YanoDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0009-0002-1468-3415
Takahiro HobaraDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0009-0001-2900-182X
Fumikazu KojimaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0009-0004-7867-2285
Yu HiramatsuDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-1217-0870
Satoshi NozumaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-4909-7769
Tomonori NakamuraDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0002-4618-9369
Yusuke SakiyamaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0003-0691-1705
Jun MitsuiDepartment of Precision Medicine Neurology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7425-4765
Shoji TsujiDepartment of Neurology, The University of Tokyo Hospital, Tokyo, Japan.
Hiroshi TakashimaDepartment of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID 0000-0003-0989-6141

Funding

Japan Agency for Medical Research and Development 201442014AJapan Agency for Medical Research and Development 201442071AJapan Society for the Promotion of Science JP18H02742Japan Society for the Promotion of Science JP20K16604Japan Society for the Promotion of Science JP21H02842Japan Society for the Promotion of Science JP21K15702Japan Society for the Promotion of Science JP22K07495Japan Society for the Promotion of Science JP22K07519Japan Society for the Promotion of Science JP22K15713Japan Society for the Promotion of Science JP23K06931Japan Society for the Promotion of Science JP23K06966Japan Society for the Promotion of Science JP24K18708Ministry of Health, Labour and Welfare 2016100002B
6 · The paper itself

Abstract

backgroundMitofusin 2 (MFN2) is a major causative gene for axonal Charcot - Marie - Tooth disease type 2A (CMT2A), with a wide phenotypic spectrum. Comprehensive large - scale genotype - phenotype association studies are essential for understanding disease pathogenesis and improved clinical management.

methodsWe conducted a nationwide retrospective study of 176 Japanese patients with genetically confirmed pathogenic or likely pathogenic MFN2 variants encompassing clinical, electrophysiological, and genetic characterization.

resultsMFN2 was the second most frequent causative gene among 1211 genetically diagnosed inherited peripheral neuropathy cases in Japan. A total of 76 MFN2 variants were identified, including nine novel likely pathogenic variants. Disease onset occurred at a mean age of 11.1 years, with distal motor weakness and tibialis anterior involvement as prominent features. Sensory symptoms were present in ~60% of patients and were more common in cases with longer disease duration. Central and systemic features, including pyramidal signs, optic atrophy, and vocal cord paralysis, were also observed. Electrophysiological studies revealed a predominantly axonal sensorimotor pattern, with relatively preserved upper limb conduction and marked lower limb abnormalities. Importantly, 24 patients (16%) were non-ambulatory, with earlier onset and greater weakness. Domain-based analysis further revealed that variant location may influence age at onset.

conclusionThis large-scale study highlights the genetic and clinical diversity of MFN2-related CMT in Japan. Our findings confirm a motor-dominant, length-dependent axonal neuropathy with additional sensory and systemic features in some cases. These results emphasize the importance of early diagnosis, genotype-informed care, and long-term follow-up in managing MFN2-related CMT.

Indexed as

Charcot-Marie-Tooth DiseaseGTP PhosphohydrolasesMitochondrial ProteinsAdolescentAdultChildChild, PreschoolEast Asian PeopleFemaleGenetic Association StudiesHumansJapanMaleMiddle AgedRetrospective StudiesYoung AdultGTP PhosphohydrolasesMFN2 protein, humanMitochondrial Proteinshmsn (charcot–marie‐tooth)neurogeneticsneuropathy

Identifiers

PMID41030121
PMCPMC12790173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.